- More Late on Auto Loan Payments in Third Quarter
- Contagion Fears Calmed by Dubai World Plan
- AIG Cuts Debt to Government by $25 Billion; Shares Up
- GM Sees China Sales Soar 110% in November
- China Hires Foreigners to Manage Forex Reserves
- Bank of Japan Offers Liquidity at Emergency Meeting
- Somali Sea Gangs Create Pirate Stock Exchange
- Cutting Jobless Will Take Time: White House's Summers
- GE, Vivendi Agree to Value NBCU Stake at $5.8 Billion
- Dubai a 'Wake Up Call'—Expect Volatility Now: Market Pro
- Treasury Threatens Banks, Not Borrowers
- We're Approaching a Market Bubble: Portfolio Manager
- Hershey Shares: What Options Are Saying
- Nov. 30: Unusual Volume Leaders
- Why Careful Shoppers Are Great for the Box Office
- Blue Nile CEO: 'We're Having the Best Cyber Monday Ever'
- Best Online Retailers to Buy Now: Internet Analyst
- ESPN The Magazine’s Body Issue: A Financial Success
MOST SHARED
- Timeless and Time-Tested Warren Buffett Watch Predictions
- Good Sign for the Economy: 'Greed' Makes a Comeback
- Dubai World Set to Restructure About $26 Billion of Total Debt
- Dubai Stocks Could Fall a Further 30%: Charts
- Treasury Threatens Banks, Not Borrowers
- Dubai Markets Close Sharply Lower for Second Day
- What to Expect from Cyber Monday
- Bove: 26 Banks May Need To Raise More Capital
- Bank of Japan Offers More Liquidity at Emergency Meeting
- Arrest Imminent in Florida Ponzi Case: Report
Text Size 
Wyeth [WYE
Loading...
()
] said quarterly earnings rose a better-than-expected 12% on strong sales of its vaccine against childhood infections, and reported positive trial results for its most important experimental drug.
The trial data shows low doses of Pristiq were effective against both depression and hot flashes and caused less nausea than seen in prior studies of higher doses. Although the new data will take more time for regulators to analyze, it could bolster prospects for its eventual approval and commercial success.
Pristiq is now awaiting U.S. approval as a treatment for both conditions. But Wyeth and investors have been concerned about a high incidence of nausea seen among patients who took the drug in earlier trials to treat depression and hot flashes.
Wyeth expects the FDA to extend its hot-flashes review by three months to examine data from the low-dose trials and expects the agency to decide by the first quarter of 2008 whether to approve Pristiq as a treatment for depression.
The company earned $1.25 billion, or 92 cents a share, compared with $1.12 billion, or 82 cents a share, in the year-ago period.
Excluding special items, Wyeth earned 94 cents a share. Analysts on average expected 87 cents a share, according to Reuters Estimates.
Total revenue in the period increased 11% to $5.4 billion for the 2007 first quarter. Prevnar, Wyeth's vaccine for infections, was the biggest gainer by sales in the quarter,
jumping 43% to $617 million.
Antidepressant Effexor continued to be Wyeth's top seller at $891 million in the period, but sales slid 6% from a year earlier due to increased competition.
Print
Email
- Ever wished your cab driver would stop chatting and just get to where you're going? Well, that moment is closer than ever.
- UPS is giving its customers the option to offset its carbon emissions when sending a package.
- Romania's presidential campaign has been rocked by a video that may show the president striking a 10-year-old boy.
- Raising alligators is hard work, and the fickle taste of rich consumers has just made it much harder, says the NY Times.
- A recent issue of ESPN Magazine was one of its top sellers ever, and it only took scantily clad athletes to make it happen.
- The continued real estate boom in China is partially fueled by a generational flood of newlyweds.
Data is a real-time snapshot *Data is delayed at least 15 minutes